Inventiva S.a. Stock News

Daix (France), Long Island City (New York, United States), December 6, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of ora

Daix (France), Long Island City (New York, United States) , December 6, 2021 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the results of a clinical thorough QT/QTc study 1 demonstrating the safety of lanifibranor on cardiac electrical activity.

Best 9 Web Development Companies In India In 2021 Inventiva

Zacks Investment Research lowered shares of Inventiva (NYSE:IVA) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports. The brokerage currently has $15.00 target price on the stock. According to Zacks, Inventiva S.A. is a clinical-stage biopharmaceutical company. It is focused on the development of [] The post Inventiva (NYSE:IVA) Rating Lowered to Hold at Zacks Investment Research appeared first on ETF Daily News .

Global Mucopolysaccharidosis Market Synopsis: To accomplish highest return on investment (ROI), its very essential to know about market parameters such as brand awareness, market landscape, possible future issues, industry trends and customer behaviour where Mucopolysaccharidosis Market report comes into play. Insights

Zacks Investment Research upgraded shares of Inventiva (NYSE:IVA) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $15.00 price objective on the stock. According to Zacks, Inventiva S.A. is a clinical-stage biopharmaceutical company. It is focused on the development []

Zacks Investment Research upgraded shares of Inventiva (NYSE:IVA) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. The firm currently has $15.00 target price on the stock. According to Zacks, Inventiva S.A. is a clinical-stage biopharmaceutical company. It is focused on the development of oral []

Inventiva S.A. (NYSE:IVA) shares saw strong trading volume on Monday after HC Wainwright raised their price target on the stock from $40.00 to $42.00. HC Wainwright currently has a buy rating on the stock. 900 shares traded hands during trading, a decline of 97% from the previous sessions volume of 27,559 shares.The stock last traded []

Inventiva S.A. (NASDAQ:IVA) gapped down before the market opened on Monday . The stock had previously closed at $14.47, but opened at $13.84. Inventiva shares last traded at $13.85, with a volume of 1,800 shares changing hands. Separately, HC Wainwright reissued a buy rating and issued a $40.00 price objective (up from $38.00) on shares []

Inventiva S.A. (IVA) CEO Frédéric Cren on Q2 2021 Results - Earnings Call Transcript

Daix (France), August 2, 2021 (GLOBE NEWSWIRE) – Inventiva S.A. (NASDAQ: IVA – EURONEXT PARIS: IVA) (the “Company”), a clinical-stage biotechnological company focused on the development of ora

Inventiva S.A. (IVEVF) CEO Frédéric Cren on Q4 2020 Results - Earnings Call Transcript

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux                           Daix (France), August 12, 2020 – Inventiva (Euronext Paris and Nasd

DESCRIPTION OF THE SHARE BUYBACK PROGRAM RESUMPTION OF THE LIQUIDITY CONTRACTListing place: Euronext Paris Code ISIN / Mnemo: FR0013233012 / IVA Website: www.inventivapharma.comParis, August 10, 20

Activist reports to the SEC from July 16 through July 22, 2020, including positions in Anterix, Inventiva, BeiGene, and two other companies